Braveheart Bio, Inc. Common Stock (BRVE NASDAQ) stock market data APIs
$20.2094
-1.42(-7%)
as of October 9, 2026
Try our APIs with
free plan!
Braveheart Bio, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Prev. Close
20.2094
Open
18.7878
High
20.2143
Low
18.5805
52 wk Range
17.86-32
Market Cap
1 803 M
Shares Outstanding
90 039 K
EPS
-2.51
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Braveheart Bio, Inc. Common Stock data using free add-ons & libraries
Get Braveheart Bio, Inc. Common Stock Fundamental Data
Braveheart Bio, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -6
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Braveheart Bio, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-09-08
- EPS/Forecast: -0.25
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Braveheart Bio, Inc. Common Stock News
New
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio, Inc. SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hype...
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of SpaceX, the largest ever public of...
Insiders Are Betting Big on These 3 Healthcare Stocks
Key Points Interested in Braveheart Bio, Inc.? Here are five stocks we like better. Insiders are heavily buying speculative pharma stocks in the third quarter, signaling confidence. Braveheart Bio an...
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls tha...
Get Braveheart Bio, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.